HK1041824B - 治療系統 - Google Patents

治療系統 Download PDF

Info

Publication number
HK1041824B
HK1041824B HK02103701.2A HK02103701A HK1041824B HK 1041824 B HK1041824 B HK 1041824B HK 02103701 A HK02103701 A HK 02103701A HK 1041824 B HK1041824 B HK 1041824B
Authority
HK
Hong Kong
Prior art keywords
nqo2
fragment
fusion
variant
derivative
Prior art date
Application number
HK02103701.2A
Other languages
English (en)
Chinese (zh)
Other versions
HK1041824A1 (en
Inventor
John Burke Philip
John Knox Richard
Original Assignee
Enzacta R & D Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzacta R & D Limited filed Critical Enzacta R & D Limited
Publication of HK1041824A1 publication Critical patent/HK1041824A1/xx
Publication of HK1041824B publication Critical patent/HK1041824B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK02103701.2A 1997-06-14 2000-04-13 治療系統 HK1041824B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712370.7A GB9712370D0 (en) 1997-06-14 1997-06-14 Therapeutic systems
GB97123707 1997-06-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK00102240.4A Addition HK1023069B (en) 1997-06-14 1998-06-15 Therapeutic systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK00102240.4A Division HK1023069B (en) 1997-06-14 1998-06-15 Therapeutic systems

Publications (2)

Publication Number Publication Date
HK1041824A1 HK1041824A1 (en) 2002-07-26
HK1041824B true HK1041824B (zh) 2002-11-15

Family

ID=10814135

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103701.2A HK1041824B (zh) 1997-06-14 2000-04-13 治療系統

Country Status (12)

Country Link
US (3) US6867231B1 (https=)
EP (2) EP0988059B8 (https=)
JP (1) JP4272263B2 (https=)
AT (1) ATE311905T1 (https=)
CA (1) CA2292608A1 (https=)
CY (1) CY1105424T1 (https=)
DE (1) DE69832702T2 (https=)
DK (1) DK0988059T3 (https=)
ES (1) ES2257810T3 (https=)
GB (2) GB9712370D0 (https=)
HK (1) HK1041824B (https=)
WO (1) WO1998057662A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9903019D0 (en) * 1999-02-10 1999-03-31 Microbiological Res Authority Nitroreductase enzymes
WO2001013086A2 (en) * 1999-08-13 2001-02-22 Brandeis University Detection of nucleic acids
CN1315529A (zh) * 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人醌蛋白还原酶9和编码这种多肽的多核苷酸
CA2460317A1 (en) * 2001-09-14 2003-03-27 Timothy A. Haystead Quinone reductase 2 and aldehyde dehydrogenase as therapeutic targets
GB0328314D0 (en) * 2003-12-05 2004-01-07 Univ Bath Therapeutics
US8114626B2 (en) * 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
JP2007521835A (ja) * 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法
RU2413731C2 (ru) 2004-04-09 2011-03-10 Чугаи Сейяку Кабусики Кайся Новые растворимые в воде пролекарства
US20060229265A1 (en) * 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
WO2016149395A1 (en) * 2015-03-16 2016-09-22 ChromaDex Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
WO2017011788A1 (en) * 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
EP3538099B1 (en) 2016-11-11 2026-04-22 The Queen's University of Belfast Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
JP7136795B2 (ja) 2016-11-29 2022-09-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 母体の健康および／または子の健康を向上させるためのｎａｄ前駆体の使用
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US440859A (en) * 1890-11-18 Wire-rope machine
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
JPS5460386A (en) * 1977-10-20 1979-05-15 Fuji Photo Film Co Ltd Photopolymerizable composition
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IL59007A (en) 1978-12-22 1983-11-30 Biogen Nv Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPS60184252A (ja) * 1984-03-02 1985-09-19 Canon Inc 電子写真感光体
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ225599A (en) 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
WO1990001063A1 (en) 1988-07-23 1990-02-08 Delta Biotechnology Limited New secretory leader sequences
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB8929097D0 (en) 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
GB9001641D0 (en) 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
CA2122036C (en) * 1991-10-23 2002-09-17 Gillian Anlezark Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form
GB9200417D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
GB9200415D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
GB9323008D0 (en) 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
GB9516943D0 (en) * 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
GB9524942D0 (en) 1995-12-06 1996-02-07 Aepact Ltd Drug therapy
WO1997024143A1 (en) * 1995-12-29 1997-07-10 Aepact Limited Cytotoxic agents
WO1998022577A1 (en) * 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
GB9624993D0 (en) 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems

Also Published As

Publication number Publication date
DK0988059T3 (da) 2006-01-23
EP0988059B8 (en) 2006-03-01
DE69832702D1 (de) 2006-01-12
US7138122B2 (en) 2006-11-21
US20030086933A1 (en) 2003-05-08
GB2341605A8 (en) 2000-03-28
ATE311905T1 (de) 2005-12-15
JP2002511754A (ja) 2002-04-16
US6867231B1 (en) 2005-03-15
EP1468698A3 (en) 2005-03-23
CA2292608A1 (en) 1998-12-23
WO1998057662A3 (en) 1999-08-12
EP0988059B1 (en) 2005-12-07
GB9928237D0 (en) 2000-01-26
GB2341605B (en) 2002-02-20
JP4272263B2 (ja) 2009-06-03
HK1041824A1 (en) 2002-07-26
DE69832702T2 (de) 2006-08-10
EP1468698A2 (en) 2004-10-20
GB2341605A (en) 2000-03-22
ES2257810T3 (es) 2006-08-01
WO1998057662A2 (en) 1998-12-23
GB9712370D0 (en) 1997-08-13
EP0988059A2 (en) 2000-03-29
HK1023069A1 (en) 2000-09-01
US20070166296A1 (en) 2007-07-19
CY1105424T1 (el) 2010-04-28

Similar Documents

Publication Publication Date Title
HK1041824A1 (en) Therapeutic systems
AU7031500A (en) Therapeutic quinazoline compounds
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
AU1922101A (en) Human fgf-21 gene and gene expression products
EP0972517A3 (en) Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumours
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
AU5309994A (en) Catheter/needle assembly kit and method for administering therapeutic agents to the subarachnoid space
IL141494A0 (en) Stable hypoxia inducible factor-1 alpha and method of use
AU7891398A (en) Method for activating human antigen presenting cells, activated human antigen presenting cells, and use of the same
AUPR177300A0 (en) Therapeutic methods
PT1137762E (pt) Tratamento da doença de pompe
CA2413736A1 (en) Thorium or actinium radionuclides for endoradionuclide therapy
IL130083A0 (en) 3-Pyridyl enantiomers and their use as analgesics
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
WO1999012951A8 (en) Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
EP1609856A3 (en) Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof
WO1998001563A3 (en) Adenovirus e4 proteins for inducing cell death
AU5323396A (en) Methods of treating inflammation and compositions therefor
EP1561462A3 (en) Anti arrhytmic composition and methods of treatment
AU4937699A (en) Use of succinic acid or salts thereof for the treatment of diabetes mellitus andwound healing
WO2001034180A3 (en) Interferon gamma for the treatment of asthma
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
AU7854094A (en) Use of amiodarone for the treatment of heart failure
AU2001220255A1 (en) Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferationof cancer cell using the expression vector

Legal Events

Date Code Title Description
PF Patent in force
AM46 Amendment of patent specifications after grant under section 46 of the patents ordinance
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100615